Table 3 FADD as a prognostic biomarker in cancer
Cancer types | Clinical values | References | |
|---|---|---|---|
HNSCC | FADD overexpression was significantly associated with worse OS (p < 0.001), DSS (p < 0.001), and DFS (p < 0.001). | Gonzalez-Moles et al. (Gonzalez-Moles et al. 2020) | |
|  | A 13-gene signature consist of FADD, GABARAPL1, ITGA3, USP10, ST13, MAPK9, PRKN, IKBKB, ITPR1, TP73, MAP2K7, CDKN2A, and EEF2K was an independent prognostic factor (p < 0.001) for NSCLC patients. The 13-gene signature significantly stratified HNSCC patients into high- and low-risk groups in terms of OS (p < 0.0001). The AUC vale were significant for both the TCGA (0.685) and GEO (0.928). | Ren et al. (Ren et al. 2021) | |
| Â | A 3-gene signature consist of FADD, EGFR, and PARK2 was an independent prognostic biomarker. ROC analyses revealed high predictive accuracy and sensitivity of the 3-gene signature. | Jiang et al. (Jiang et al. 2021) | |
|  | A 6-gene signature consist of FADD, EGFR, HSPB8, PRKN, CDKN2A, and ITGA3 was an independent prognostic biomarker (AUC = 0.709) for NSCLC patients. | Yang et al. (Yang et al. 2020a) | |
|  | Lower FADD expression was significantly correlated with better OS (p = 0.0001) and DFS (p = 0.0006) in HNSCC patients with lymph node metastasis. | Fan et al. (Fan et al. 2013) | |
|  | A 7-gene signature consist of FADD, ITGA3, CDKN2A, NKX2-3, BAK1, CXCR4, and HSPB8 was proved to be effective in predicting the survival rate of HNSCC patients (p = 8.409 × 10− 6). | Jin et al. (Jin and Qin 2020) | |
NSCLC | Lung ADC patients with overexpression of FADD exhibited significantly lower OS rates (p = 0.033). FADD overexpression was an independent poor prognostic biomarker for patients with surgically resected lung ADC (p = 0.027). | Chen et al. (Chen et al. 2021) | |
ESCC | A 13-gene signature consist of FADD, PARP1, ITGA6 was an independent prognostic factor for ESCC patients. This signature effectively stratified patients in both discovery and validation cohorts by OS (p = 5.162E-8 and p = 0.052, respectively). | Cui et al. (Cui et al. 2021) | |
BC | FADD expression was significantly associated with T stage (P = 0.046) in BC patients. The combination of FADD, PPFIA1, and TMEM16A gene expressions was significantly correlated with perineural invasion (p = 0.022). Moreover, the combination of the three gene expressions was closely associated with DFS (p = 0.034). | Choi et al. (Choi et al. 2014) | |
Lymphoma | The phosphorylation of FADD (Ser194) was identified as a prognostic biomarker in T-cell lymphoblastic lymphoma. | Marin-Rubio et al. (Marin-Rubio et al. 2019a) | |
| Â | Low or absent expression of the FADD in leukemic cells was identified as a poor independent prognostic biomarker. | (Tourneur et al. 2004) | |
Lung cancer | A 6-gene signature consist of FADD, EIF4EBP1, TP63, BNIP3, ATIC, and ERO1A was identified as an independent prognostic biomarker for lung adenocarcinoma and lung squamous cell carcinoma. | Zhu et al. (Zhu et al. 2020) | |
OSCC | FADD gene copy number and protein expression were identified as potential prognostic biomarkers in patients with OSCC. Patients with both FADD copy number amplification and high protein expression exhibited the shortest DFS (p = 0.074 and p = 0.002) and OS (p = 0.011 and p = 0.027). | Chien et al. (Chien et al. 2016) | |